BIOFILCHEM share price, P/E, ROE & financials

As of 6 Nov 2026, Biofil Chemicals & Pharmaceuticals trades at 181.0× trailing earnings, above the industry P/E of 28.7×, and the shares are 34% below their 52-week high. It earns ROCE of 16% and ROE of 14%, and sales fell 1.9% a year over 3 years while net profit grew 71%. Debt is 0.14× equity. It is a small-cap company with a market cap of ₹50 Cr, ranked 130th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares fell 24% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year

Open: ₹30.23
Day high: ₹31.11
Day low: ₹30.23
Prev. close: ₹30.23
Volume: 13.7K

Health check

1 good · 2 fair · 3 to check

ReturnsBehind
−23.7% over a year, better than 0 of 7 peers.
Price tagPricier
P/E 181.0 vs industry 28.7.
GrowthSteady
Sales −1.9%, profit +70.7% a year over 3 years.
ProfitabilityAverage
ROCE 15.6% vs peer median 17.9%.
Balance sheetSolid
Debt 0.14× equity, interest covered 380.1×, Piotroski 6 of 9.
Red flags3 to check
Quarterly profit down 95.5% on a year ago.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹50 Cr, #130 of 154 in its industry by size.

Defensive

Beta 0.58 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Jun 2026: sales ₹35 Cr · profit ₹0 Cr

Market cap: ₹50 Cr; Small cap
P/E: 181.0; Industry 28.7
Price to book: 2.33; Peers 4.99
Dividend yield: 0.00%
ROE: 13.8%; Peers 14.7%
ROCE: 15.6%; Peers 17.9%
Debt to equity: 0.14; Debt ₹3.02 Cr
EPS (TTM): ₹0.17; Face value ₹10
OPM (TTM): 2.3%; Net margin 1.4%
Sales growth: +92.0%; Latest quarter vs a year ago
Profit growth: −95.5%; Latest quarter vs a year ago
Price to sales: 1.45; EV/EBITDA 44.6

Strengths

Quarterly sales up 92.0% on a year ago.

Risks to check

Quarterly profit down 95.5% on a year ago.
P/E of 181.0 against an industry P/E of 28.7.
34% below its 52-week high.

Derived automatically from reported figures. Not a recommendation.

About Biofil Chemicals & Pharmaceuticals

Biofil Chemicals and Pharmaceuticals Limited engages in the manufacturing and trading of pharmaceutical products in India. It operates through Pharma and Chemical segments. The company offers basic drugs and chemicals, including sodium chloride, potassium chloride, sodium citrate, diethyl carbamazine citrate, ferrous sulphate, dried ferrous sulphate, ferrus fumerate, micro crystalline cellulose, and dicyclomine hydrochloride. It also provides ferrous…

Headquarters: Indore
Employees: 24
Sector: Healthcare
ISIN: INE829A01014
Website: biofilgroup.net

Price range

52 weeks

₹25.60₹46.34

Today

₹30.23₹31.11

Avg volume (3M): 42.8K
1-year return: minus 23.7%
From 52-week high: minus 33.6%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peers Screen the whole industry

Company
SUNPHARMASun Pharmaceutical Industries	1,860.00	plus 1.69%	4,46,276	40.7	4.99	17.9%	13.1%	28.2%	10.4%	10.6%	0.86%	plus 8.2%
DIVISLABDivi's Laboratories	10,320.50	plus 1.78%	2,73,977	93.6	16.35	19.0%	16.2%	34.9%	11.0%	12.1%	0.29%	plus 49.0%
TORNTPHARMTorrent Pharmaceuticals	4,750.00	plus 0.85%	1,80,675	80.2	9.83	9.1%	15.7%	33.7%	13.3%	20.2%	0.80%	plus 31.7%
LAURUSLABSLaurus Labs	2,340.00	minus 0.26%	1,26,433	94.4	20.86	19.5%	24.0%	30.4%	3.8%	4.0%	0.09%	plus 138.6%
ZYDUSLIFEZydus Lifesciences	1,197.90	plus 0.41%	1,19,491	28.6	4.29	19.0%	14.7%	26.2%	16.5%	37.0%	0.08%	plus 22.8%
DRREDDYDr. Reddy's Laboratories	1,373.00	plus 0.51%	1,14,462	40.9	2.96	14.2%	7.3%	15.9%	11.0%	−1.7%	0.58%	plus 13.8%
CIPLACipla	1,411.00	plus 0.49%	1,13,993	39.4	3.22	14.9%	8.3%	17.3%	7.2%	11.5%	0.92%	minus 6.6%
BIOFILCHEMBiofil Chemicals & Pharmaceuticals	30.77	plus 1.79%	50	181.0	2.33	15.6%	13.8%	2.3%	−1.9%	70.7%	0.00%	minus 23.7%
Median of 7 peers	–	0.51%	1,26,433	40.9	4.99	17.9%	14.7%	28.2%	11.0%	11.5%	0.58%	22.8%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Jun 25	Sep 25	Dec 25	Mar 26	Jun 26
6.4	13.5	0.9	7.6	12.4
6.4	13.4	0.8	7.1	12.2
0	0.1	0.1	0.4	0.1
0.1%	0.8%	11.1%	5.7%	1.1%
2.8	0.1	0.1	0.1	0.1
0	0	0	0	0
0.1	0.1	0.1	0.1	0.1
2.8	0.1	0.1	0.5	0.1
12.7%	25.2%	25.8%	54.7%	18.6%
2.4	0.1	0.1	0.2	0.1
1.48	0.05	0.05	0.13	0.07

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: −1.9%
Profit CAGR 3Y: +70.7%
EPS CAGR 3Y: +71.3%
ROE: 13.8%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
30	40	33.4	28.4
–	+33.3%	minus 16.6%	minus 15.0%
28.9	39.2	32.6	27.7
1.2	0.8	0.8	0.6
3.9%	2.0%	2.5%	2.3%
0.1	0.5	0.3	0.3
0	0	0	0
0.4	0.4	0.4	0.3
–	–	–	2.8
0.8	0.9	0.7	3.4
29.3%	18.0%	24.2%	19.2%
0.6	0.7	0.6	2.8
–	+26.6%	minus 21.4%	+399.6%
0.34	0.44	0.34	1.71

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
16.3	16.3	16.3	16.3
1	1.9	2.5	5.3
0.5	0.4	0.5	3
13.6	28.4	31.7	18.3
31.4	47.1	51	42.8
9	8.6	8.3	6.9
0	2.3	0.3	3.3
22.4	36.2	42.4	32.6
31.4	47.1	51	42.8

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
−0.1	2.4	−1.9	−0.6
−0	−0	−0.1	1.1
0	−0.1	−0	2.5
−0.1	2.2	−2	3.1
−0	−0	−0.1	−0.2
−0.1	2.4	−2	−0.8

Shareholding pattern

Source: NSE filings

46.8%

promoters

Promoters46.79%
Public53.21%
As of 30 Sep 2026

Quarter	Promoters	Public	Promoter change
30 Sep 2026	46.79%	53.21%	0.00
30 Jun 2026	46.79%	53.21%	0.00
31 Mar 2026	46.79%	53.21%	0.00
31 Dec 2025	46.79%	53.21%	0.00
30 Sep 2025	46.79%	53.21%	–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you